Indian API companies to grow by 7-8% and operating profit margin to improve to 12-14% in FY2025: ICRA

Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024

Novo Nordisk's H1 sales increased by 24% in Danish kroner

For the 2024 outlook, sales growth is now expected to be 22-28% at CER

Zydus’ new drug application of Desidustat tablets accepted by China Medical System Holdings

Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients

IOL Chemicals and Pharmaceuticals Q2 PAT jumps 141% to Rs. 37.8 Cr

EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ

Defending Public Health: Strategies to safeguard pharmaceutical quality: Raheel Shah, Business Development Director, BDR Pharmaceuticals

This exposé embarks on an illuminative journey, unfurling the crucial stratagems imperative for upholding public health, achieved through the unyielding fortress of pharmaceutical quality safeguards

India’s MRI systems market to reach $950 million by 2030, forecasts GlobalData

India will account for about 18% of the Asia-Pacific (APAC) MRI systems market in 2023

Alembic Pharmaceuticals receives USFDA approvals for 5 products in Q1FY24

Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.

Fortis Healthcare to divest its Vadapalani, Chennai Hospital business operations to Kauvery Group of Hospitals

Cipla partners with MNCs to strengthen anti-diabetes innovative portfolio: GlobalData

Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.

India’s Covid success story hailed the world over as a role model in Crisis Management, says Dr. Singh

India's strategy against Covid was more effective than any other countries in the world